Urinary stone matrix

The urinary stone matrix refers to the complex structural framework of renal calculi (kidney stones), consisting of an inorganic mineral phase and an organic matrix. The organic matrix typically accounts for 2-10% of the stone's dry weight and is composed of various proteins (such as osteopontin, uromodulin, and calgranulin), lipids, and glycosaminoglycans that facilitate the nucleation, growth, and aggregation of mineral crystals [10, 14]. In clinical pharmacology, this matrix is the primary target for litholytic therapies designed to dissolve existing stones and preventive treatments that inhibit the biochemical processes leading to stone formation [13]. Drugs like potassium citrate act by increasing urinary citrate levels, which binds to calcium and inhibits crystal aggregation within the matrix, while agents like acetohydroxamic acid target the enzymatic production of ammonia to prevent the formation of struvite stones [13, 14]. Understanding the composition and regulation of the stone matrix is essential for developing targeted therapies to manage urolithiasis and prevent its recurrence.

Other names

Kidney stone matrixRenal stone matrixOrganic matrix of urinary calculiMineral stone matrix

Inhibition of crystal nucleation, growth, and aggregation within the organic framework; dissolution of the mineral-matrix complex through chelation or pH modification.